|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, 15 October 2005, Vol. 106, No. 8, pp. 2600.
HIT as a preventable disease?MCMASTER UNIVERSITY
Martel and colleagues report their meta-analysis of thromboprophylaxis studies comparing the frequency of heparin-induced thrombocytopenia (HIT) between patient groups receiving unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH). Their study supports the view that HIT is a preventable disease.
In this same issue of Blood, Greinacher and colleagues2 provide further data in line with this meta-analysis. Notably, in this single-institution study of postorthopedic surgery thromboprophylaxis (providing further information regarding 1 of the studies3 in the meta-analysis), the lower risk of HIT with LMWH was responsible for a significant overall reduction in symptomatic thrombosis (both HIT and non-HIT) in patients receiving LMWH compared with UFH:3.9% versus 0.7% (P = .028).
Martel and colleagues point out that the impact of LMWH on reducing frequency of HIT is shown most convincingly for orthopedic surgery patients, a patient population that comprised 4 of the 5 studies in their meta-analysis that evaluated HIT as an outcome. Recently, the 7th ACCP Conference on Antithrombotic and Thrombolytic Therapy regarded the greater risk of HIT as a reason to recommend against the use of UFH for thromboprophylaxis in postorthopedic surgery patients.1 An important issue is whether the reduced risk of HIT with LMWH extends beyond postorthopedic surgery thromboprophylaxis, and can be generalized to other patient populations. This seems likely, based on a French study4 that estimated an overall 40-fold reduction in frequency of HIT with LMWH, based upon an analysis of the "numerator" of HIT cases attributed to either UFH or LMWH, and the corresponding "denominator" of estimated use of these 2 heparin preparations. Thus, HIT (and associated thrombosis) can be regarded as a preventable disease, by selection of less HIT-inducing LMWH and related compounds (fondaparinux, danaparoid) for otherwise appropriate patients. Ideally, further studies evaluating differences in risk of HIT (or its surrogate marker, platelet-activating, antiplatelet factor 4/heparin antibodies) between UFH and LMWH in different clinical settings should be performed. It is tempting to contemplate UFH perhaps someday joining ticlopidine as a "historical relic" as both become supplanted by their safer counterparts (LMWH and clopidogrel, respectively). Nevertheless, as there are certain situations (cardiopulmonary by-pass, vascular surgery, hemodialysis) in which the shorter half-life of UFH and its neutralization by protamine offer major advantages over LMWH, and because HIT sometimes occurs with LMWH (0.2% frequency estimated by Martel and colleagues), it seems that the preventable disease, HIT, will further decline—but not disappear—in the foreseeable future.
Footnotes
The author has declared a financial interest in a company whose product was discussed in the present work.
References
  CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
||||
| |||||||||||
| Copyright © 2005 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||||
